Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
LFVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Lifevantage Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lifevantage Corporation
Event history 50
Past FDA Catalysts and PDUFA Decisions
How LFVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LFVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BEINDORFF MICHAEL ADirector | Sell | -10,000 31,625 held | $4.89 | 11/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LFVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LFVN for Q3 2026. | ||||
Ownership Trends
LFVN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How LFVN ranks across every disease it competes in
LFVN News
LifeVantage Declares Quarterly Dividend
LifeVantage Corporation announced a quarterly cash dividend of $0.050 per share, approved by its Board of Directors. This dividend will be paid to stockholders on December 15, 2026, who are on record as of December 1, 2026. The company emphasizes its commitment to health and wellness through its diverse product offerings.
Read more →LifeVantage Announces Financial Results for the First Quarter Fiscal 2027
LifeVantage Corporation reported a challenging first quarter for fiscal 2027, with revenue of $37.1 million, a 22.0% decrease year-over-year. The net loss was $0.2 million, or $0.02 per diluted share, compared to a profit of $2.2 million last year. The company aims to transform into a more consumer-focused brand and improve its operational efficiency.
Read more →New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*
LifeVantage Corporation's recent study investigates how Protandim® Nrf2 can protect cells from five environmental toxins, including pollution and microplastics. The research indicates that cells treated with Protandim® exhibited significantly lower oxidative stress compared to those exposed to toxins alone. This study reinforces LifeVantage's role in nutrigenomics and cellular health.
Read more →LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026
LifeVantage Corporation will announce its financial results for Q1 FY 2027 on November 9, 2026. The results will be released after market close, followed by a conference call at 2:30 p.m. MT. Investors can participate via phone or a live webcast, which will be archived for 30 days.
Read more →LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LifeVantage Corporation announced inducement awards for CEO Terrence Moorehead, granted under Nasdaq Listing Rule 5635(c)(4). The awards include 128,824 restricted stock units and up to 289,855 performance-based stock units, contingent on achieving specific financial targets. This move aims to enhance executive retention and align interests with company performance.
Read more →LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026
LifeVantage Corporation announced its participation in the WTR Virtual Insights Conference on September 23, 2026. CEO Terrence Moorehead and CFO Carl Aure will present, starting at 1:30 p.m. ET. The event is accessible to all investors, who can register via the company's Investor Relations website.
Read more →LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026
LifeVantage Corporation reported a 23.1% decline in revenue for Q4 FY 2026, totaling $42.4 million. Net income per diluted share decreased to $0.10 from $0.15 a year earlier. For the full fiscal year, revenue fell by 20.1% to $182.6 million, attributed to lower sales and order sizes. Despite these challenges, CEO Terrence Moorehead remains optimistic about the company's future.
Read more →LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2026 Results on August 27, 2026
LifeVantage Corporation will announce its fourth quarter and full fiscal year 2026 results on August 27, 2026. The announcement will be made after market close, followed by a conference call at 2:30 p.m. MT. Investors can participate via phone or a live webcast.
Read more →LifeVantage Welcomes Terrence Moorehead as Chief Executive Officer
LifeVantage Corporation has appointed Terrence Moorehead as President and CEO. Moorehead, who has over 25 years of experience in consumer wellness, previously led Nature's Sunshine Products through a successful transformation. His leadership is anticipated to enhance LifeVantage's growth and operational capabilities as the company seeks to create long-term value.
Read more →LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026
LifeVantage Corporation (Nasdaq: LFVN) reported third-quarter fiscal 2026 results, showing a revenue decline of 25.2% compared to the same period last year, primarily attributed to reduced sales of its MindBody GLP-1 System. The company's net income per diluted share dropped to $0.11, down from $0.26, while adjusted EBITDA also fell significantly. Despite these challenges, LifeVantage emphasized its strong balance sheet, share repurchase activities, and an increase in its cash dividend. The company aims to enhance performance through strategic initiatives and product launches moving forward.
Read more →LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026
LifeVantage Corporation will release its third quarter fiscal results on May 6, 2026. The announcement follows the end of the quarter on March 31, 2026. A conference call for investors is set for the same day, with a live webcast also available. The company focuses on health and wellness products.
Read more →LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack
LifeVantage Corporation announced the granting of U.S. Patent No. 12,589,067 B2 for its Healthy Glow Essentials Stack. This patent, issued on March 31, 2026, recognizes the product's ability to activate cellular signaling genes and improve skin health. The combination of Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen enhances antioxidant production and collagen maintenance.
Read more →LifeVantage Inspires with ‘Breakthrough’ Announcements at 2026 Momentum Academy in Las Vegas
LifeVantage Corporation concluded its Momentum Academy event in Las Vegas, focusing on business growth and product innovation. The event featured new AXIO flavors and a U.S. Patent for its Healthy Glow Essentials Stack. Keynote speaker Brian Biro motivated attendees, while CEO Steve Fife announced his upcoming retirement, introducing Terrence Moorehead as his successor.
Read more →LifeVantage Appointing Terrence Moorehead as Chief Executive Officer
LifeVantage Corporation has appointed Terrence Moorehead as the new President and Chief Executive Officer, effective August 5, 2026. Moorehead, who has over 25 years of experience in leading transformations within the health and wellness industry, previously served as CEO of Nature's Sunshine Products, where he achieved significant revenue and EBITDA growth. His appointment follows the planned retirement of the former CEO, Steve Fife, and the Board expresses confidence in Moorehead's ability to guide the company through its next phase of growth. The interim leadership team will maintain operations until Moorehead officially joins the company.
Read more →LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026
LifeVantage Corporation will participate in the Water Tower Research Insights Conference on April 15, 2026. Key executives, including CEO Steve Fife, will present at the event, which is open to all investors. The webcast will start at approximately 12:30 p.m. Eastern Time. Interested parties can register via the company's Investor Relations website.
Read more →LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal
LifeVantage Corporation announced its expansion into Portugal, set for May 2026. The company will introduce flagship products such as Protandim and TrueScience, aiming to attract purpose-driven entrepreneurs and wellness seekers. This move supports LifeVantage's international growth strategy and commitment to delivering wellness solutions globally.
Read more →LifeVantage to Participate in the Sidoti Small Cap Conference
LifeVantage Corporation will participate in the Sidoti Small Cap Conference on March 18-19, 2026. CEO Steve Fife and CFO Carl Aure will present virtually on March 19 at 4:00 p.m. Eastern Time. A live webcast of the presentation will be available on the company's Investor Relations website.
Read more →